Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Japan approves Opdivo, the first-ever immuno-oncology agent for unresectable advanced/recurrent gast

pharmaasiaSeptember 27, 2017

Tag: gastric cancer , Opdivo

PharmaSources Customer Service